Taselisib

Generic Name: Taselisib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₈N_₈O_₂

CAS Number: 1282512-48-4

Unique Ingredient Identifier: L08J2O299M

Background: Taselisib has been used in trials studying the treatment and basic science of LYMPHOMA, Breast Cancer, Ovarian Cancer, Solid Neoplasm, and HER2/Neu Negative, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Advanced Lymphoma
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma

Interventions: Drug: Taselisib

First Posted Date: 2020-06-19

Last Posted Date: 2024-11-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT04439175

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Phase 2

Completed

Conditions: Stage IV Squamous Cell Lung Carcinoma
Recurrent Squamous Cell Lung Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Taselisib

First Posted Date: 2016-05-30

Last Posted Date: 2020-10-23

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 31

Registration Number: NCT02785913

Locations: 🇺🇸
Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States

and more 1100 locations

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Breast Carcinoma
Cervical Carcinoma
Liver Carcinoma
Malignant Uterine Neoplasm
Recurrent Gastric Carcinoma
Recurrent Head and Neck Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Prostate Carcinoma
Recurrent Rectal Carcinoma

Interventions: Drug: Afatinib
Drug: Capivasertib
Drug: Binimetinib
Drug: Adavosertib
Procedure: Biospecimen Collection
Other: Cytology Specimen Collection Procedure
Drug: Afatinib Dimaleate
Drug: Dabrafenib
Drug: Defactinib
Drug: Fexagratinib
Drug: Dasatinib
Drug: Ipatasertib
Procedure: Biopsy
Drug: Crizotinib
Drug: Dabrafenib Mesylate
Drug: Taselisib
Drug: Sapanisertib
Drug: PI3K-beta Inhibitor GSK2636771
Drug: Defactinib Hydrochloride
Drug: Palbociclib
Biological: Nivolumab
Drug: Copanlisib
Drug: Ulixertinib
Biological: Trastuzumab Emtansine
Drug: Copanlisib Hydrochloride
Biological: Relatlimab
Procedure: Computed Tomography
Drug: Trametinib
Biological: Pertuzumab
Drug: Erdafitinib
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Drug: Larotrectinib
Procedure: Echocardiography
Drug: Osimertinib
Biological: Trastuzumab
Drug: Larotrectinib Sulfate
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Vismodegib
Drug: Sunitinib Malate
Procedure: Radionuclide Imaging

First Posted Date: 2015-06-08

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6452

Registration Number: NCT02465060

Locations: 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸
Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States

and more 1416 locations

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Estrogen Receptor Positive
Stage IV Breast Cancer
Estrogen Receptor Negative
Progesterone Receptor Negative
Progesterone Receptor Positive
HER2/Neu Negative
Triple-Negative Breast Carcinoma

Interventions: Other: Biomarker Analysis
Drug: Enzalutamide
Other: Pharmacological Study
Drug: Taselisib

First Posted Date: 2015-05-29

Last Posted Date: 2022-08-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT02457910

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 9 locations

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer
Recurrent Breast Cancer

Interventions: Drug: Taselisib
Drug: Trastuzumab emtansine
Drug: Pertuzumab
Drug: Trastuzumab
Drug: Paclitaxel

First Posted Date: 2015-03-17

Last Posted Date: 2024-10-02

Lead Sponsor: Otto Metzger, MD

Target Recruit Count: 68

Registration Number: NCT02390427

Locations: 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Taselisib
Drug: Placebo
Drug: Fulvestrant

First Posted Date: 2015-01-16

Last Posted Date: 2022-07-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 631

Registration Number: NCT02340221

Locations: 🇦🇹
Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I, Graz, Austria
🇦🇹
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Wien, Austria
🇧🇬
Complex Oncological Center - Plovdiv, EOOD, Plovdiv, Bulgaria

and more 154 locations

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Letrozole
Other: Placebo
Drug: Taselisib

First Posted Date: 2014-10-24

Last Posted Date: 2018-05-21

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 334

Registration Number: NCT02273973

Locations: 🇦🇹
Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie, Graz, Austria
🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇭🇺
Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika, Debrecen, Hungary

and more 114 locations

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Completed

Conditions: Recurrent Squamous Cell Lung Carcinoma
Stage IV Squamous Cell Lung Carcinoma AJCC v7

Interventions: Biological: Durvalumab
Drug: Docetaxel
Drug: FGFR Inhibitor AZD4547
Drug: Erlotinib Hydrochloride
Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Drug: Taselisib
Drug: Palbociclib
Biological: Nivolumab
Biological: Rilotumumab
Other: Pharmacological Study
Drug: Talazoparib
Biological: Tremelimumab

First Posted Date: 2014-06-03

Last Posted Date: 2023-06-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1864

Registration Number: NCT02154490

Locations: 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States

and more 997 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy